C. David James, Ph.D. - Publications

Affiliations: 
Neurological Surgery University of California, San Francisco, San Francisco, CA 
Area:
EGF receptor, PTEN, EAG2, BRAFV600E kinase, CDKN2A
Website:
http://neurosurgery.ucsf.edu/index.php/research_btrc_james.html

110 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 McKinney A, Lindberg OR, Engler JR, Chen KY, Kumar A, Gong H, Lu KV, Simonds EF, Cloughesy TF, Liau LM, Prados M, Bollen AW, Berger MS, Shieh JTC, James CD, et al. Mechanisms of resistance to EGFR inhibition reveal metabolic vulnerabilities in human GBM. Molecular Cancer Therapeutics. PMID 31270152 DOI: 10.1158/1535-7163.MCT-18-1330  0.76
2019 Sabelström H, Quigley D, Fenster T, Foster DJ, Fuchshuber CAM, Saxena S, Yuan E, Li N, Paterno F, Phillips JJ, James CD, Norling B, Berger MS, Persson AI. High density is a property of slow-cycling and treatment-resistant human glioblastoma cells. Experimental Cell Research. PMID 30844389 DOI: 10.1016/j.yexcr.2019.03.003  0.76
2018 Taylor JW, Parikh M, Phillips JJ, James CD, Molinaro AM, Butowski NA, Clarke JL, Oberheim-Bush NA, Chang SM, Berger MS, Prados M. Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. Journal of Neuro-Oncology. PMID 30151703 DOI: 10.1007/s11060-018-2977-3  0.76
2016 Grossauer S, Koeck K, Murphy NE, Meyers ID, Daynac M, Truffaux N, Truong AY, Nicolaides TP, McMahon M, Berger MS, Phillips JJ, James CD, Petritsch CK. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. Oncotarget. PMID 27713119 DOI: 10.18632/oncotarget.12419  0.76
2016 Olow A, Mueller S, Yang X, Hashizume R, Meyerowitz J, Weiss WA, Resnick AC, Waanders AJ, Stalpers LJ, Berger MS, Gupta N, James CD, Petritsch CK, Haas-Kogan DA. BRAF status in personalizing treatment approaches for pediatric gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27217440 DOI: 10.1158/1078-0432.CCR-15-1101  0.76
2016 Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, ... ... James CD, et al. Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell. 29: 563-73. PMID 27070703 DOI: 10.1016/j.ccell.2016.03.012  0.84
2016 Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, James CD, Mueller S, Haas-Kogan DA. Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. Journal of Neuro-Oncology. PMID 26782702 DOI: 10.1007/s11060-015-2024-6  0.76
2015 Lerner RG, Grossauer S, Kadkhodaei B, Meyers I, Sidorov M, Koeck K, Hashizume R, Ozawa T, Phillips JJ, Berger MS, Nicolaides T, James CD, Petritsch CK. Targeting a Plk1-controlled polarity checkpoint in therapy-resistant glioblastoma-propagating cells. Cancer Research. PMID 26573800 DOI: 10.1158/0008-5472.CAN-14-3689  0.76
2015 Li N, Maly DJ, Chanthery YH, Sirkis DW, Nakamura JL, Berger MS, James CD, Shokat KM, Weiss WA, Persson AI. Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastoma. Molecular Cancer Therapeutics. 14: 419-28. PMID 25522764 DOI: 10.1158/1535-7163.MCT-14-0526  0.76
2015 Feng H, Li Y, Yin Y, Zhang W, Hou Y, Zhang L, Li Z, Xie B, Gao WQ, Sarkaria JN, Raizer JJ, James CD, Parsa AT, Hu B, Cheng SY. Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor α. Neuro-Oncology. 17: 832-42. PMID 25468898 DOI: 10.1093/neuonc/nou323  0.84
2014 Clark AJ, Safaee M, Oh T, Ivan ME, Parimi V, Hashizume R, Ozawa T, James CD, Bloch O, Parsa AT. Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells. Journal of Translational Medicine. 12: 345. PMID 25464980 DOI: 10.1186/s12967-014-0345-4  0.84
2014 Yoshida Y, Ozawa T, Yao TW, Shen W, Brown D, Parsa AT, Raizer JJ, Cheng SY, Stegh AH, Mazar AP, Giles FJ, Sarkaria JN, Butowski N, Nicolaides T, James CD. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification. Molecular Cancer Therapeutics. 13: 2919-29. PMID 25313012 DOI: 10.1158/1535-7163.MCT-14-0306  0.84
2014 Oh T, Fakurnejad S, Sayegh ET, Clark AJ, Ivan ME, Sun MZ, Safaee M, Bloch O, James CD, Parsa AT. Immunocompetent murine models for the study of glioblastoma immunotherapy. Journal of Translational Medicine. 12: 107. PMID 24779345 DOI: 10.1186/1479-5876-12-107  0.84
2014 Kaur G, Sayegh ET, Larson A, Bloch O, Madden M, Sun MZ, Barani IJ, James CD, Parsa AT. Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neuro-Oncology. 16: 628-36. PMID 24696499 DOI: 10.1093/neuonc/nou025  0.84
2014 Fouse SD, Nakamura JL, James CD, Chang S, Costello JF. Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype. Neuro-Oncology. 16: 361-71. PMID 24311636 DOI: 10.1093/neuonc/not223  0.84
2014 Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, ... ... James CD, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science (New York, N.Y.). 343: 72-6. PMID 24310612 DOI: 10.1126/science.1241328  0.84
2014 Mueller S, Hashizume R, Yang X, Kolkowitz I, Olow AK, Phillips J, Smirnov I, Tom MW, Prados MD, James CD, Berger MS, Gupta N, Haas-Kogan DA. Targeting Wee1 for the treatment of pediatric high-grade gliomas. Neuro-Oncology. 16: 352-60. PMID 24305702 DOI: 10.1093/neuonc/not220  0.84
2013 Hadaczek P, Ozawa T, Soroceanu L, Yoshida Y, Matlaf L, Singer E, Fiallos E, James CD, Cobbs CS. Cidofovir: a novel antitumor agent for glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6473-83. PMID 24170543 DOI: 10.1158/1078-0432.CCR-13-1121  0.84
2013 Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA, ... ... James CD, et al. Frequent truncating mutations of STAG2 in bladder cancer. Nature Genetics. 45: 1428-30. PMID 24121789 DOI: 10.1038/ng.2800  0.84
2013 Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, ... ... James CD, et al. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5722-32. PMID 24030701 DOI: 10.1158/1078-0432.CCR-13-0527  0.84
2013 Brauer MJ, Zhuang G, Schmidt M, Yao J, Wu X, Kaminker JS, Jurinka SS, Kolumam G, Chung AS, Jubb A, Modrusan Z, Ozawa T, James CD, Phillips H, Haley B, et al. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3681-92. PMID 23685835 DOI: 10.1158/1078-0432.CCR-12-3635  0.84
2013 Weng KC, Hashizume R, Noble CO, Serwer LP, Drummond DC, Kirpotin DB, Kuwabara AM, Chao LX, Chen FF, James CD, Park JW. Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models. Nanomedicine (London, England). 8: 1913-25. PMID 23631502 DOI: 10.2217/nnm.12.209  0.84
2013 Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, ... ... James CD, et al. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discovery. 3: 534-47. PMID 23533263 DOI: 10.1158/2159-8290.CD-12-0502  0.48
2013 James CD. Aberrant miRNA expression in brain tumors: a subject attracting an increasing amount of attention. Neuro-Oncology. 15: 405. PMID 23530133 DOI: 10.1093/neuonc/not045  0.84
2013 Wade A, Robinson AE, Engler JR, Petritsch C, James CD, Phillips JJ. Proteoglycans and their roles in brain cancer. The Febs Journal. 280: 2399-417. PMID 23281850 DOI: 10.1111/febs.12109  0.84
2013 Chen PY, Ozawa T, Drummond DC, Kalra A, Fitzgerald JB, Kirpotin DB, Wei KC, Butowski N, Prados MD, Berger MS, Forsayeth JR, Bankiewicz K, James CD. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro-Oncology. 15: 189-97. PMID 23262509 DOI: 10.1093/neuonc/nos305  0.84
2013 Park I, Hu S, Bok R, Ozawa T, Ito M, Mukherjee J, Phillips JJ, James CD, Pieper RO, Ronen SM, Vigneron DB, Nelson SJ. Evaluation of heterogeneous metabolic profile in an orthotopic human glioblastoma xenograft model using compressed sensing hyperpolarized 3D 13C magnetic resonance spectroscopic imaging. Magnetic Resonance in Medicine. 70: 33-9. PMID 22851374 DOI: 10.1002/mrm.24434  0.84
2012 Hashizume R, Smirnov I, Liu S, Phillips JJ, Hyer J, McKnight TR, Wendland M, Prados M, Banerjee A, Nicolaides T, Mueller S, James CD, Gupta N. Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment. Journal of Neuro-Oncology. 110: 305-13. PMID 22983601 DOI: 10.1007/s11060-012-0973-6  0.84
2012 Engler JR, Robinson AE, Smirnov I, Hodgson JG, Berger MS, Gupta N, James CD, Molinaro A, Phillips JJ. Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. Plos One. 7: e43339. PMID 22937035 DOI: 10.1371/journal.pone.0043339  0.84
2012 Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, Yang H, Tanaka K, Oba-Shinjo SM, Uno M, Inda MM, Wykosky J, Bachoo RM, James CD, DePinho RA, et al. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proceedings of the National Academy of Sciences of the United States of America. 109: 14164-9. PMID 22891331 DOI: 10.1073/pnas.1211962109  0.84
2012 Chaumeil MM, Gini B, Yang H, Iwanami A, Sukumar S, Ozawa T, Pieper RO, Mischel PS, James CD, Berger MS, Ronen SM. Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla. Neuro-Oncology. 14: 1050-61. PMID 22670012 DOI: 10.1093/neuonc/nos126  0.84
2012 Huillard E, Hashizume R, Phillips JJ, Griveau A, Ihrie RA, Aoki Y, Nicolaides T, Perry A, Waldman T, McMahon M, Weiss WA, Petritsch C, James CD, Rowitch DH. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proceedings of the National Academy of Sciences of the United States of America. 109: 8710-5. PMID 22586120 DOI: 10.1073/pnas.1117255109  0.84
2012 Toussaint LG, Nilson AE, Goble JM, Ballman KV, James CD, Lefranc F, Kiss R, Uhm JH. Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion. Molecular Cancer. 11: 32. PMID 22583806 DOI: 10.1186/1476-4598-11-32  0.84
2012 James CD. Nanoparticles for treating brain tumors: unlimited possibilities. Neuro-Oncology. 14: 389. PMID 22436865 DOI: 10.1093/neuonc/nos075  0.84
2012 Serwer LP, James CD. Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations. Advanced Drug Delivery Reviews. 64: 590-7. PMID 22306489 DOI: 10.1016/j.addr.2012.01.004  0.84
2012 Aoki Y, Hashizume R, Ozawa T, Banerjee A, Prados M, James CD, Gupta N. An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing. Journal of Neuro-Oncology. 108: 29-35. PMID 22231932 DOI: 10.1007/s11060-011-0796-x  0.84
2012 Goldhoff P, Clarke J, Smirnov I, Berger MS, Prados MD, James CD, Perry A, Phillips JJ. Clinical stratification of glioblastoma based on alterations in retinoblastoma tumor suppressor protein (RB1) and association with the proneural subtype. Journal of Neuropathology and Experimental Neurology. 71: 83-9. PMID 22157621 DOI: 10.1097/NEN.0b013e31823fe8f1  0.84
2012 Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD, Ronen SM. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro-Oncology. 14: 315-25. PMID 22156546 DOI: 10.1093/neuonc/nor209  0.84
2012 Bryce AH, Rao R, Sarkaria J, Reid JM, Qi Y, Qin R, James CD, Jenkins RB, Boni J, Erlichman C, Haluska P. Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors. Investigational New Drugs. 30: 1934-41. PMID 21881915 DOI: 10.1007/s10637-011-9742-1  0.84
2012 Chaumeil MM, Ozawa T, Park I, Scott K, James CD, Nelson SJ, Ronen SM. Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma. Neuroimage. 59: 193-201. PMID 21807103 DOI: 10.1016/j.neuroimage.2011.07.034  0.84
2011 James CD. Stimulating anti-tumor immune response: the problem of regulatory T-cells. Neuro-Oncology. 13: 1261. PMID 22113488 DOI: 10.1093/neuonc/nor201  0.84
2011 Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, ... ... James CD, et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discovery. 1: 442-56. PMID 22059152 DOI: 10.1158/2159-8290.CD-11-0102  0.48
2011 Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, ... ... James CD, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4482-90. PMID 22025148 DOI: 10.1200/JCO.2010.33.8715  0.84
2011 Serwer LP, Noble CO, Michaud K, Drummond DC, Kirpotin DB, Ozawa T, Prados MD, Park JW, James CD. Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts. Neuro-Oncology. 13: 1288-95. PMID 21954443 DOI: 10.1093/neuonc/nor139  0.84
2011 Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, Toretsky JA, Rosenberg SA, Shukla N, Ladanyi M, Samuels Y, James CD, Yu H, Kim JS, Waldman T. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (New York, N.Y.). 333: 1039-43. PMID 21852505 DOI: 10.1126/science.1203619  0.84
2011 James CD. Evolution of mouse models for studying CNS cancer: a decade of progress. Neuro-Oncology. 13: 691. PMID 21727207 DOI: 10.1093/neuonc/nor089  0.84
2011 Park I, Bok R, Ozawa T, Phillips JJ, James CD, Vigneron DB, Ronen SM, Nelson SJ. Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging. Journal of Magnetic Resonance Imaging : Jmri. 33: 1284-90. PMID 21590996 DOI: 10.1002/jmri.22563  0.84
2011 Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, Prados MD, Haas-Kogan DA. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro-Oncology. 13: 384-92. PMID 21317208 DOI: 10.1093/neuonc/noq193  0.84
2011 Uhm JH, Ballman KV, Wu W, Giannini C, Krauss JC, Buckner JC, James CD, Scheithauer BW, Behrens RJ, Flynn PJ, Schaefer PL, Dakhill SR, Jaeckle KA. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. International Journal of Radiation Oncology, Biology, Physics. 80: 347-53. PMID 20510539 DOI: 10.1016/j.ijrobp.2010.01.070  0.84
2010 Serwer L, Hashizume R, Ozawa T, James CD. Systemic and local drug delivery for treating diseases of the central nervous system in rodent models. Journal of Visualized Experiments : Jove. PMID 20736920 DOI: 10.3791/1992  0.84
2010 Ozawa T, James CD. Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging. Journal of Visualized Experiments : Jove. PMID 20644517 DOI: 10.3791/1986  0.84
2010 Zhu X, Bidlingmaier S, Hashizume R, James CD, Berger MS, Liu B. Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells. Molecular Cancer Therapeutics. 9: 2131-41. PMID 20587664 DOI: 10.1158/1535-7163.MCT-09-1059  0.84
2010 James CD. Tumor-initiating cells: an influential paradigm for xenograft research. Neuro-Oncology. 12: 519. PMID 20530515 DOI: 10.1093/neuonc/noq053  0.84
2010 Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, Lau J, Masic S, Nguyen K, Yakovenko S, Zhe XN, Gilmer HC, Collins R, Nagaoka M, Phillips JJ, ... ... James CD, et al. Pleiotropic role for MYCN in medulloblastoma. Genes & Development. 24: 1059-72. PMID 20478998 DOI: 10.1101/gad.1907510  0.84
2010 James CD. p53 in malignant glioma: 20 years later and still much to learn. Neuro-Oncology. 12: 421. PMID 20406892 DOI: 10.1093/neuonc/noq037  0.84
2010 Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour LL, Rivers CS, Modrusan Z, Nacu S, Guerrero S, Edgar KA, Wallin JJ, ... ... James CD, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell. 17: 362-75. PMID 20385361 DOI: 10.1016/j.ccr.2009.12.049  0.84
2010 Michaud K, Solomon DA, Oermann E, Kim JS, Zhong WZ, Prados MD, Ozawa T, James CD, Waldman T. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Research. 70: 3228-38. PMID 20354191 DOI: 10.1158/0008-5472.CAN-09-4559  0.84
2010 Hashizume R, Gupta N, Berger MS, Banerjee A, Prados MD, Ayers-Ringler J, James CD, VandenBerg SR. Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing. Neuro-Oncology. 12: 366-76. PMID 20308314 DOI: 10.1093/neuonc/nop033  0.84
2010 Park I, Larson PE, Zierhut ML, Hu S, Bok R, Ozawa T, Kurhanewicz J, Vigneron DB, Vandenberg SR, James CD, Nelson SJ. Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors. Neuro-Oncology. 12: 133-44. PMID 20150380 DOI: 10.1093/neuonc/nop043  0.84
2010 Ward CS, Venkatesh HS, Chaumeil MM, Brandes AH, Vancriekinge M, Dafni H, Sukumar S, Nelson SJ, Vigneron DB, Kurhanewicz J, James CD, Haas-Kogan DA, Ronen SM. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Research. 70: 1296-305. PMID 20145128 DOI: 10.1158/0008-5472.CAN-09-2251  0.84
2010 Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, ... ... James CD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17: 98-110. PMID 20129251 DOI: 10.1016/j.ccr.2009.12.020  0.84
2010 Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Research. 70: 512-9. PMID 20068183 DOI: 10.1158/0008-5472.CAN-09-1851  0.84
2010 Costa BM, Smith JS, Chen Y, Chen J, Phillips HS, Aldape KD, Zardo G, Nigro J, James CD, Fridlyand J, Reis RM, Costello JF. Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Research. 70: 453-62. PMID 20068170 DOI: 10.1158/0008-5472.CAN-09-2189  0.84
2010 Hashizume R, Ozawa T, Dinca EB, Banerjee A, Prados MD, James CD, Gupta N. A human brainstem glioma xenograft model enabled for bioluminescence imaging. Journal of Neuro-Oncology. 96: 151-9. PMID 19585223 DOI: 10.1007/s11060-009-9954-9  0.84
2009 Sughrue ME, Yang I, Kane AJ, Rutkowski MJ, Fang S, James CD, Parsa AT. Immunological considerations of modern animal models of malignant primary brain tumors. Journal of Translational Medicine. 7: 84. PMID 19814820 DOI: 10.1186/1479-5876-7-84  0.84
2009 Silber J, James CD, Hodgson JG. microRNAs in gliomas: small regulators of a big problem. Neuromolecular Medicine. 11: 208-22. PMID 19731102 DOI: 10.1007/s12017-009-8087-9  0.84
2009 Carlson BL, Grogan PT, Mladek AC, Schroeder MA, Kitange GJ, Decker PA, Giannini C, Wu W, Ballman KA, James CD, Sarkaria JN. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. International Journal of Radiation Oncology, Biology, Physics. 75: 212-9. PMID 19695438 DOI: 10.1016/j.ijrobp.2009.04.026  0.84
2009 Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, ... ... James CD, et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Research. 69: 6889-98. PMID 19690143 DOI: 10.1158/0008-5472.CAN-09-0347  0.48
2009 Kadoch C, Dinca EB, Voicu R, Chen L, Nguyen D, Parikh S, Karrim J, Shuman MA, Lowell CA, Treseler PA, James CD, Rubenstein JL. Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1989-97. PMID 19276270 DOI: 10.1158/1078-0432.CCR-08-2054  0.84
2009 James CD, Cavenee WK. Stem cells for treating glioblastoma: how close to reality? Neuro-Oncology. 11: 101. PMID 19237733 DOI: 10.1215/15228517-2009-016  0.84
2009 Hodgson JG, Yeh RF, Ray A, Wang NJ, Smirnov I, Yu M, Hariono S, Silber J, Feiler HS, Gray JW, Spellman PT, Vandenberg SR, Berger MS, James CD. Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro-Oncology. 11: 477-87. PMID 19139420 DOI: 10.1215/15228517-2008-113  0.84
2009 Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, ... ... James CD, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 579-84. PMID 19075262 DOI: 10.1200/JCO.2008.18.9639  0.84
2009 Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, Wu W, James CD, Sarkaria JN. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro-Oncology. 11: 281-91. PMID 18952979 DOI: 10.1215/15228517-2008-090  0.84
2008 Dinca EB, Lu KV, Sarkaria JN, Pieper RO, Prados MD, Haas-Kogan DA, Vandenberg SR, Berger MS, James CD. p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Research. 68: 10034-9. PMID 19074867 DOI: 10.1158/0008-5472.CAN-08-1687  0.84
2008 Yi JM, Tsai HC, Glöckner SC, Lin S, Ohm JE, Easwaran H, James CD, Costello JF, Riggins G, Eberhart CG, Laterra J, Vescovi AL, Ahuja N, Herman JG, Schuebel KE, et al. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Research. 68: 8094-103. PMID 18829568 DOI: 10.1158/0008-5472.CAN-07-6208  0.84
2008 Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF, Bergers G, Weiss WA, Alvarez-Buylla A, Hodgson JG. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. Bmc Medicine. 6: 14. PMID 18577219 DOI: 10.1186/1741-7015-6-14  0.84
2008 Yang L, Clarke MJ, Carlson BL, Mladek AC, Schroeder MA, Decker P, Wu W, Kitange GJ, Grogan PT, Goble JM, Uhm J, Galanis E, Giannini C, Lane HA, James CD, et al. PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3993-4001. PMID 18559622 DOI: 10.1158/1078-0432.CCR-07-4152  0.84
2008 Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, Wick W. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2900-8. PMID 18483356 DOI: 10.1158/1078-0432.CCR-07-1719  0.84
2008 Chi JH, Panner A, Cachola K, Crane CA, Murray J, Pieper RO, James CD, Parsa AT. Increased expression of the glioma-associated antigen ARF4L after loss of the tumor suppressor PTEN. Laboratory investigation. Journal of Neurosurgery. 108: 299-303. PMID 18240926 DOI: 10.3171/JNS/2008/108/2/0299  0.84
2008 Baia GS, Dinca EB, Ozawa T, Kimura ET, McDermott MW, James CD, VandenBerg SR, Lal A. An orthotopic skull base model of malignant meningioma. Brain Pathology (Zurich, Switzerland). 18: 172-9. PMID 18093250 DOI: 10.1111/j.1750-3639.2007.00109.x  0.84
2008 McAvoy S, Zhu Y, Perez DS, James CD, Smith DI. Disabled-1 is a large common fragile site gene, inactivated in multiple cancers. Genes, Chromosomes & Cancer. 47: 165-74. PMID 18008369 DOI: 10.1002/gcc.20519  0.84
2007 McAvoy S, Ganapathiraju S, Perez DS, James CD, Smith DI. DMD and IL1RAPL1: two large adjacent genes localized within a common fragile site (FRAXC) have reduced expression in cultured brain tumors. Cytogenetic and Genome Research. 119: 196-203. PMID 18253029 DOI: 10.1159/000112061  0.84
2007 Liu C, Sarkaria JN, Petell CA, Paraskevakou G, Zollman PJ, Schroeder M, Carlson B, Decker PA, Wu W, James CD, Russell SJ, Galanis E. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 7155-65. PMID 18056196 DOI: 10.1158/1078-0432.CCR-07-1306  0.84
2007 McAvoy S, Ganapathiraju SC, Ducharme-Smith AL, Pritchett JR, Kosari F, Perez DS, Zhu Y, James CD, Smith DI. Non-random inactivation of large common fragile site genes in different cancers. Cytogenetic and Genome Research. 118: 260-9. PMID 18000379 DOI: 10.1159/000108309  0.84
2007 Dinca EB, Sarkaria JN, Schroeder MA, Carlson BL, Voicu R, Gupta N, Berger MS, James CD. Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. Journal of Neurosurgery. 107: 610-6. PMID 17886562 DOI: 10.3171/JNS-07/09/0610  0.84
2007 Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, ... ... James CD, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 2288-94. PMID 17538175 DOI: 10.1200/JCO.2006.08.0705  0.84
2007 Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, Schroeder MA, Galanis E, Giannini C, Wu W, Dinca EB, James CD. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Molecular Cancer Therapeutics. 6: 1167-74. PMID 17363510 DOI: 10.1158/1535-7163.MCT-06-0691  0.84
2007 Paraskevakou G, Allen C, Nakamura T, Zollman P, James CD, Peng KW, Schroeder M, Russell SJ, Galanis E. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 677-86. PMID 17299404 DOI: 10.1038/sj.mt.6300105  0.84
2007 Yung WK, James CD. Mapping the future of Neuro-Oncology. Neuro-Oncology. 9: 1-2. PMID 17170381 DOI: 10.1215/15228517-2006-027  0.84
2007 Gonzalez-Paz N, Chng WJ, McClure RF, Blood E, Oken MM, Van Ness B, James CD, Kurtin PJ, Henderson K, Ahmann GJ, Gertz M, Lacy M, Dispenzieri A, Greipp PR, Fonseca R. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood. 109: 1228-32. PMID 16840723 DOI: 10.1182/blood-2006-05-024661  0.84
2007 Yung WKA, James CD. Editorial: Focusing in, broadening our reach Neuro-Oncology. 9: 81. DOI: 10.1215/15228517-2006-041  0.84
2006 Pollack IF, Hamilton RL, James CD, Finkelstein SD, Burnham J, Yates AJ, Holmes EJ, Zhou T, Finlay JL. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. Journal of Neurosurgery. 105: 418-24. PMID 17328268 DOI: 10.3171/ped.2006.105.5.418  0.84
2006 Allen C, Vongpunsawad S, Nakamura T, James CD, Schroeder M, Cattaneo R, Giannini C, Krempski J, Peng KW, Goble JM, Uhm JH, Russell SJ, Galanis E. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Research. 66: 11840-50. PMID 17178881 DOI: 10.1158/0008-5472.CAN-06-1200  0.84
2006 Gallia GL, Rand V, Siu IM, Eberhart CG, James CD, Marie SK, Oba-Shinjo SM, Carlotti CG, Caballero OL, Simpson AJ, Brock MV, Massion PP, Carson BS, Riggins GJ. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Molecular Cancer Research : McR. 4: 709-14. PMID 17050665 DOI: 10.1158/1541-7786.MCR-06-0172  0.84
2006 Sarkaria JN, Carlson BL, Schroeder MA, Grogan P, Brown PD, Giannini C, Ballman KV, Kitange GJ, Guha A, Pandita A, James CD. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2264-71. PMID 16609043 DOI: 10.1158/1078-0432.CCR-05-2510  0.84
2006 Bigner DD, Yung WKA, James CD, Cohn SA. Neuro-Oncology: Editorial Neuro-Oncology. 8: 289. DOI: 10.1215/15228517-2006-018  0.84
2006 Aldape K, Colman H, James CD. Models of malignant glioma Drug Discovery Today: Disease Models. 3: 191-196. DOI: 10.1016/j.ddmod.2006.06.002  0.84
2005 Rao RD, Mladek AC, Lamont JD, Goble JM, Erlichman C, James CD, Sarkaria JN. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia (New York, N.Y.). 7: 921-9. PMID 16242075 DOI: 10.1593/neo.05361  0.84
2005 Panner A, James CD, Berger MS, Pieper RO. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Molecular and Cellular Biology. 25: 8809-23. PMID 16199861 DOI: 10.1128/MCB.25.20.8809-8823.2005  0.84
2005 Su Z, Emdad L, Sauane M, Lebedeva IV, Sarkar D, Gupta P, James CD, Randolph A, Valerie K, Walter MR, Dent P, Fisher PB. Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells. Oncogene. 24: 7552-66. PMID 16044151 DOI: 10.1038/sj.onc.1208911  0.84
2005 Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, Schroeder MA, James CD. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro-Oncology. 7: 164-76. PMID 15831234 DOI: 10.1215/S1152851704000821  0.84
2005 Bigner DD, James CD, Cohn SA. Neuro-Oncology impact factor for 2004 Neuro-Oncology. 7: 423-424. DOI: 10.1215/S1152851705200066  0.84
2005 Berger MS, James CD. Gliomas: Advances in molecular analysis and characterizatio - Commentary Surgical Neurology. 64: 294. DOI: 10.1016/j.surneu.2005.04.001  0.84
2004 Rao RD, James CD. Altered molecular pathways in gliomas: an overview of clinically relevant issues. Seminars in Oncology. 31: 595-604. PMID 15497113 DOI: 10.1053/j.seminoncol.2004.07.002  0.84
2004 Olson JJ, James CD, Lawson D, Hunter S, Tang G, Billingsley J. Correlation of the response of recurrent malignant gliomas treated with interferon alpha with tumor interferon alpha gene content. International Journal of Oncology. 25: 419-27. PMID 15254740  0.84
2004 Yacoub A, Mitchell C, Hong Y, Gopalkrishnan RV, Su ZZ, Gupta P, Sauane M, Lebedeva IV, Curiel DT, Mahasreshti PJ, Rosenfeld MR, Broaddus WC, James CD, Grant S, Fisher PB, et al. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biology & Therapy. 3: 739-51. PMID 15197348  0.84
2004 Pandita A, Aldape KD, Zadeh G, Guha A, James CD. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes, Chromosomes & Cancer. 39: 29-36. PMID 14603439 DOI: 10.1002/gcc.10300  0.84
2003 Rao RD, Uhm JH, Krishnan S, James CD. Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies. Frontiers in Bioscience : a Journal and Virtual Library. 8: e270-80. PMID 12700121  0.84
2003 Park S, James CD. Lanthionine synthetase components C-like 2 increases cellular sensitivity to adriamycin by decreasing the expression of P-glycoprotein through a transcription-mediated mechanism. Cancer Research. 63: 723-7. PMID 12566319  0.84
2003 Krishnan S, Rao RD, James CD, Sarkaria JN. Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas. Frontiers in Bioscience : a Journal and Virtual Library. 8: e1-13. PMID 12456322  0.84
Show low-probability matches.